Basic Information
| LncRNA/CircRNA Name | MIR22HG |
| Synonyms | NA |
| Region | GRCh38_17:1711493-1717174 |
| Ensemble | ENSG00000186594 |
| Refseq | NR_028502 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | |||
| Variant | Cell Growth | Circulating | 2 | ||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | hepatocellular carcinoma |
| ICD-0-3 | C22.0 |
| Methods | qPCR, RIP, Western blot |
| Sample | hepatocellular carcinoma tissues, cell lines(HL-7702, MHCC-97H, SK-Hep-1, HepG2, SMMC-7721, Huh7, HCC-LM3) |
| Expression Pattern | down-regulated |
| Function Description | MIR22HG expression was significantly down-regulated in 4 independent HCC cohorts compared to that in controls. Its low expression was associated with tumor progression and poor prognosis of patients with HCC. Forced expression of MIR22HG in HCC cells significantly suppressed proliferation, invasion, and metastasis in vitro and in vivo. Mechanistically, MIR22HG derived miR-22-3p to target high mobility group box 1 (HMGB1), thereby inactivating HMGB1 downstream pathways. Human MIR22HG consists of 4 transcripts (variants 1-4, Figure S1A). We detected the expression of these 4 transcripts in 7 paired HCC tissues and corresponding non-tumor tissues, and found that variant 1 was the most abundant isoform in non-tumor tissues, but was dramatically downregulated in tumor tissues. |
| Pubmed ID | 30083257 |
| Year | 2018 |
| Title | Identification and Functional Characterization of Long Non-coding RNA MIR22HG as a Tumor Suppressor for Hepatocellular Carcinoma. |
External Links
| Links for MIR22HG | GenBank HGNC NONCODE |
| Links for hepatocellular carcinoma | OMIM COSMIC |